이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Dupilumab을 투여받은 아토피성 피부염이 있는 6세 이상의 프랑스 참가자에 대한 장기 데이터 수집 연구 (DUPILAB)

2026년 11월 18일 업데이트: Sanofi

아토피성 피부염에 대해 Dupilumab을 투여받은 환자에 대한 프랑스의 전향적 관찰 연구.

This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

관찰

등록 (실제)

303

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Amiens, 프랑스, 80054
        • Investigational Site Number: 2500041
      • Angers, 프랑스, 49000
        • Investigational Site Number: 2500037
      • Argenteuil, 프랑스, 95107
        • Investigational Site Number: 2500021
      • Armentières, 프랑스, 59280
        • Investigational Site Number: 2500044
      • Arras, 프랑스, 62000
        • Investigational Site Number: 2500018
      • Ars-Laquenexy, 프랑스, 57530
        • Investigational Site Number: 2500011
      • Avignon, 프랑스, 84000
        • Investigational Site Number: 2500023
      • Besançon, 프랑스, 25000
        • Investigational Site Number: 2500001
      • Bron, 프랑스, 69500
        • Investigational Site Number: 2500003
      • Caen, 프랑스, 14033
        • Investigational Site Number: 2500043
      • Chambéry, 프랑스, 73000
        • Investigational Site Number: 2500050
      • Clermont-Ferrand, 프랑스, 63113
        • Investigational Site Number: 2500006
      • Dijon, 프랑스, 21231
        • Investigational Site Number: 2500005
      • Epagny Metz Tessy, 프랑스, 74370
        • Investigational Site Number: 2500004
      • Fort-de-France, 프랑스, 97261
        • Investigational Site Number: 2500039
      • La Tronche, 프랑스, 38700
        • Investigational Site Number: 2500045
      • Le Havre, 프랑스, 76083
        • Investigational Site Number: 2500019
      • Le Mans, 프랑스, 72037
        • Investigational Site Number: 2500040
      • Les Sables-d'Olonne, 프랑스, 85100
        • Investigational Site Number: 2500038
      • Levallois-Perret, 프랑스, 92300
        • Investigational Site Number: 2500048
      • Lille, 프랑스, 59037
        • Investigational Site Number: 2500032
      • Limoges, 프랑스, 87000
        • Investigational Site Number: 2500002
      • Lorient, 프랑스, 56100
        • Investigational Site Number: 2500036
      • Marseille, 프랑스, 13008
        • Investigational Site Number: 2500029
      • Montpellier, 프랑스, 34090
        • Investigational Site Number: 2500028
      • Nantes, 프랑스, 44093
        • Investigational Site Number: 2500024
      • Nice, 프랑스, 06000
        • Investigational Site Number: 2500025
      • Nice, 프랑스, 6300
        • Investigational Site Number: 2500020
      • Pau, 프랑스, 64000
        • Investigational Site Number: 2500016
      • Poitiers, 프랑스, 86000
        • Investigational Site Number: 2500042
      • Pontoise, 프랑스, 95300
        • Investigational Site Number: 2500022
      • Périgueux, 프랑스, 24019
        • Investigational Site Number: 2500009
      • Romans-sur-Isère, 프랑스, 26102
        • Investigational Site Number: 2500014
      • Rouen, 프랑스, 76031
        • Investigational Site Number: 2500008
      • Saint-Germain-en-Laye, 프랑스, 78100
        • Investigational Site Number: 2500015
      • Saint-Mandé, 프랑스, 94163
        • Investigational Site Number: 2500027
      • Saint-Nazaire, 프랑스, 44606
        • Investigational Site Number: 2500026
      • Saint-Pierre, 프랑스, 97410
        • Investigational Site Number: 2500035
      • Saint-Pierre, 프랑스, 97448
        • Investigational Site Number: 2500013
      • Toulouse, 프랑스, 31059
        • Investigational Site Number: 2500012
      • Valence, 프랑스, 26000
        • Investigational Site Number: 2500010
      • Vandœuvre-lès-Nancy, 프랑스, 54500
        • Investigational Site Number: 2500031

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

The population of interest for this study will be patients in France aged 6 years old or more with a diagnosis of AD either severe or moderate to severe (depending on age group) who initiate dupilumab in real world setting. The study will be conducted in real conditions of practice, dupilumab will be prescribed at the sole initiative of the participating physician irrespective of patient enrolment decision.

설명

Inclusion Criteria:

  • Male or female, 6 years or older.
  • Initiating treatment with dupilumab for AD according to French-specific prescribing information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe AD). The decision of initiation of the treatment is independent to the study's participation.
  • Able to understand and complete study-related questionnaires.
  • Signed informed consent form. For participants <18 years old, Informed consent form signed by the parent/legal guardian and participant's assent obtained.

Exclusion Criteria:

  • Patients who have a contraindication to the drug according to the French-specific prescribing information label.
  • Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments.
  • Patients currently participating in any interventional clinical trial.
  • Patients previously treated with dupilumab.
  • Patients under tutorship or curatorship; patients under safeguard of justice or deprived of his/her liberty by an administrative or court decision.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Participants with AD treated with dupilumab

Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.

Dupilumab cohort

다른 이름들:
  • SAR231893
  • 듀피젠트®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
AD 치료를 위해 두필루맙을 투여받은 참가자의 체중 특성
기간: 기준선에서
기준선에서
AD 치료를 위해 두필루맙을 투여받은 참가자의 신장 특성
기간: 기준선에서
기준선에서
동반질환 및 치료는 기준치에서 변경됩니다.
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
아토피 동반질환 및 치료는 기준치와 달라졌습니다.
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
두필루맙 용량의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
두필루맙 투여의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
치료에 대한 두필루맙 순응도의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
두필루맙 임시 또는 영구 중단 시 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
두필루맙 치료의 기준선에서 다른 치료법으로 전환
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
병용 AD 치료에 대한 두필루맙 치료의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
Demographic characteristics of participants who receive dupilumab for AD
기간: At baseline

Including age, gender, educational level, socio-professional category

At baseline
Medical history characteristics of participants who receive dupilumab for AD
기간: At baseline

including previous treatments for AD, relevant medical history, family history of atopy

At baseline
Change from baseline in lifestyle habits of participants who receive dupilumab for AD
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable

Including alcohol, tobacco, CBD and cannabis consumption

At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)
기간: At month 6, month 12, month 18, month 24, month 30, month 36

PGATE for patients ≥ 12 years of age: an internally developed and validated instrument allowing patients to rate their opinion and perceived treatment effect. Ratings are on a 5-point Likert scale from 1 being "Poor" and 5 being "Excellent".

At month 6, month 12, month 18, month 24, month 30, month 36
Change in eczema severity using the Eczema Area and Severity Index (EASI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

EASI is a validated measure used to assess severity and extent of AD at each body region by multiplying the lesions characteristics score x the body area score x multiplier. Four AD disease characteristics -erythema, thickness (induration, population, and oedema), scratching (excoriation), and lichenification - will each be assessed for severity by the observing physician, as follows: 0 = none, absent; 1=mild (just perceptible); 2=Moderate (obvious); 3=Severe. The area score ranges from 0 to 6 is determined as follows: 0= 0% (no active eczema in region); 1= 1-9%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89%; 6= 90-100% (entire region affected by eczema). The multiplier is determined according to the region affected and the age of the patient: 0.1 or 0.2 for patients < 8 years old (head/neck), 0.2 (upper limbs), 0.3 (trunk), 0.4 or 0.3 for patients < 8 years old (lower limbs). A higher score means higher AD severity. Scores range from 0 (no disease) to 72 (maximal disease severity).

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

ADCT for patients aged ≥ 12 years of age: a validated, brief and easily scored tool consisting of six concise questions allowing to rate the different dimensions of patient-perceived AD control, to foster communication between patients and their physicians and help appropriate decision-making. The instrument includes 6 items, with a 7-day recall period: overall severity of symptoms, frequency of intense episodes of itching, severity of bother, frequency of sleep impact, severity of daily activities impact and severity of mood or emotions impact. Each item is rated on a 5-point Likert scale, ranging from 0 (none/ not at all/ no nights) to 4 (very severe/ everyday/ extremely/ every night); the total score ranges from 0 to 24, which is the summation of the responses to all the items. A total score of ≥7 points was derived as the threshold to identify patients "not in control", based on optimal sensitivity/ specificity values. The higher the score, the less AD is controlled.

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in itch assessment
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in sleep disturbance NRS
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

PGADS for patients ≥ 12 years of age: an internally developed and validated instrument allowing to the patients to rate their AD-related overall well-being. Patients will be asked: "Considering all the ways in which your eczema affects you, how well are you doing?" Response choices will be from 1 being "Poor" to 5 being "Excellent".

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

CGAD for patients 6 to 11 years of age: an internally developed and validated instrument allowing to the caregivers to rate their child's AD-related overall well-being. Caregivers will be asked: "Considering all the way in which the eczema affects your child, how well is your child doing?". Response choices will be 1 being "Poor" to 5 being "Excellent".

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatology Life Quality Index (DLQI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

DLQI for patients ≥ 16 years (or cDLQI for patients < 16 at baseline) are 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life in adults and pediatrics, respectively. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess quality of life over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor quality of life. Patients 6-11 years old will be assisted for questionnaire completion. A cDLQI's cartoon version could be also used for patients from 6 to 11 years old. If a patient turns 16 years old during the study, they will switch to DLQI.

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatitis Family Impact Questionnaire (DFI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

DFI is a 10-item, validated questionnaire assessing the impact of AD on the QoL of the parents/legal representatives and family members of affected children. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess Quality of Life (QoL) over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QoL. It is designed to be completed by adults (aged 16 years or over) who have a child (up to and including the age of 15 years 11 months) in the family with atopic dermatitis.

At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

The EQ-5D-3L is completed by patients≥18 years old and by parent/legal representative of patients<18 years old. It consists of 2 parts:

  • The EQ-5D descriptive system has five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 3 levels: no problems, some problems, and extreme problems. The patient selects the most appropriate statement in each of the five dimensions, resulting in a 1-digit number for each dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
  • The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scale is numbered 0 to 100. A higher value represents better health and a lower value represents worse health.
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)
기간: At month 6, month 12, month 18, month 24, month 30, month 36

WPAI-AD for adults and WPAI-CIQ-AD for adolescents is a questionnaire designed to assess the impact of AD on the patient's productivity. The WPAI-AD is the version of the original generic WPAI that is specific to AD. It is a 6-item, validated questionnaire to measure impairments in work and activities over a 7-day recall period. The WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. If a patient turns 18 years old during the study, this one will switch to WPAI-AD.

At month 6, month 12, month 18, month 24, month 30, month 36
Number of Adverse Events (AE)
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

AEs for dupilumab and/or concomitant treatments will be collected throughout the study.

At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in Drug Survival
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot.

At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 28일

기본 완료 (추정된)

2028년 7월 5일

연구 완료 (추정된)

2028년 7월 5일

연구 등록 날짜

최초 제출

2023년 12월 5일

QC 기준을 충족하는 최초 제출

2023년 12월 5일

처음 게시됨 (실제)

2023년 12월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 18일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • OBS17668
  • U1111-1279-3469 (레지스트리 식별자: ICTRP)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .